In the first half of 2021, these 11 Hillhouse invested biomedical companies have officially IPO!

Source: Guanlan Pharmaceutical

Public information shows that since 2021, 11 Hillhouse invested biomedical companies have officially IPO on different stock exchanges

1.

Keji Pharmaceutical is a clinical-stage biomedical company focusing on innovative cell therapies for the treatment of solid tumors and hematological malignancies

It is reported that Keji Pharmaceutical has established an ongoing pipeline of 11 candidate products, and 6 of them are in the clinical development stage

2.

Century Therapeutics is committed to using the potential of adult stem cells to develop cell therapy products for the treatment of cancer to overcome the limitations of the first generation of cell therapy

According to reports, Century Therapeutics’ pre-clinical R&D projects include a variety of induced pluripotent stem cell-derived CAR-iT and CAR-iNK cell products, which are intended to be developed for the treatment of blood cancers and solid tumors

3.

Lyell Immunopharma aims to "reprogram" T cells to develop T cell therapies with the potential for "curing" solid tumors

According to reports, Lyell’s LYL797 is an ongoing CAR-T therapy targeting the ROR1 antigen.

4.

Talaris Therapeutics is committed to developing treatments through one-time cell therapy to permanently solve the problem of long-term immunosuppressive therapy for organ transplant patients

The side effects of long-term use of immunosuppressive drugs made Talaris’ founder, Dr.
Suzanne Ildstad, determined to develop an innovative therapy to improve the body’s immune tolerance
.
Her research found that there are facilitating cells in the bone marrow.
These cells are different from stem cells.
They can help stem cells transplanted into the host to migrate into the bone marrow, where they can generate immune cells and other blood cells
.
In addition, promoting cells can also enhance the host's immune tolerance and reduce the risk of graft-versus-host disease (GVHD)
.
According to reports, the cell therapy FCR001 developed by Talaris has entered the later stage of clinical trials.
It is planned to develop and treat patients who have previously received living donor kidney transplantation and patients with severe autoimmune diseases
.
Previously, the FDA has granted FCR001 Orphan Drug Designation and Regenerative Medicine Advanced Therapy Designation (RMAT)
.

5.
Zhaoke Ophthalmology

Research field: innovative ophthalmic drugs

Zhaoke Ophthalmology is committed to discovering, developing and commercializing ophthalmic therapies
.
Through independent development or licensed introduction, Zhaoke Ophthalmology has established a comprehensive ophthalmic drug pipeline containing 25 drug candidates (including 13 innovative drugs and 12 generic drugs), covering most major ophthalmic adaptations affecting the anterior and posterior segments of the eye Disease
.
In April 2021, Zhaoke Ophthalmology was officially listed on the Hong Kong Stock Exchange
.

It is reported that Zhaoke Ophthalmology’s initial research and development focuses on five major ophthalmic indications in China, namely dry eye (DED), wet age-related macular degeneration (wAMD), diabetic macular edema (DME), myopia and glaucoma
.
Due to the existence of multiple pathological processes, the development of many ophthalmic diseases is divided into multiple stages
.
Therefore, most ophthalmic diseases are heterogeneous diseases
.
For different ophthalmic indications, Zhaoke Ophthalmology’s development strategy is to select and develop multiple candidate drugs with different mechanisms of action, hoping to provide patients with flexible treatment options through monotherapy or combined administration
.

6.
Design Therapeutics

Research Field: Autoimmune Disease

Design Therapeutics is committed to the development of drugs for the treatment of severe degenerative diseases caused by the amplification of nucleotide repeats.
The company will be listed on the Nasdaq in March 2021
.
Nucleotide repeat disease is a type of genetic disease caused by the repeated amplification of certain short sequences of genes
.
Depending on its location, repetitive sequences may cause changes in gene expression regulation or produce toxic gene products, and they are considered to be important factors in causing degenerative diseases
.

According to the official website of Design Therapeutics, the company currently has two major research projects
.
One of the indications for the research project is Friedreich's ataxia (Friedreich's ataxia, FA) patients
.
FA is one of the most common types of hereditary ataxia.
Due to mutations in the FXN gene, the production of frataxin is limited, leading to various debilitating symptoms and complications
.
Another indication for the research project is myotonic dystrophy type-1 (DM1)
.
DM1 is a single-gene, autosomal dominant, progressive neuromuscular disease caused by mutations in the DMPK gene, which affects skeletal muscle, heart, brain and other organs
.
The main features of the disease include muscle weakness, muscle rigidity (slow muscle relaxation) and early cataracts
.
In addition, affected individuals often experience arrhythmia and neuropsychological changes
.

7.
Instil Bio

Research Field: Cell Therapy

Instil Bio is a global clinical-stage cell therapy company dedicated to the development of tumor infiltrating lymphocyte therapy for the treatment of cancer.
The company was listed on the Nasdaq in March 2021
.
Information on Instil Bio's official website shows that the company's product under development with the fastest research progress is ITIL-168, and its clinical trial for the treatment of advanced melanoma is already in the phase 1 clinical trial stage
.
In addition, ITIL-168 is also intended to be developed for the treatment of skin squamous cell carcinoma (CSCC), non-small cell lung cancer (NSCLC) and cervical cancer
.

In addition to the above-mentioned companies, Hillhouse invested in Nanomicro Technology (research area: nano microspheres), Angel of Time (research area: oral devices), Xintong Medical (research area: heart valve), Beikang Medical (research area: in vitro diagnostics) ) Has also been IPO this year
.
Due to space limitations, this article will not introduce them one by one
.

From the current point of view, Hillhouse's IPO in 2021 will focus on innovative new-generation gene therapy and cell therapy drugs
.
In terms of the types of companies it invests in, science and technology companies with strong innovation and R&D capabilities and in the early stages are more popular
.
For most of these projects, Hillhouse has made multiple rounds of investment and is a long-term supporter of these companies
.